MedTrace Logo

Low Dose Ketamine Intra Nasal Traumatology

NCT03233035 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1102

Last updated 2019-07-02

No results posted yet for this study

Summary

To evaluate the efficacy and safety of early administration of low-dose intranasal ketamine analgesic agents in patients with moderate to severe pain in the ED in reducing the need for opioid or non opioids analgesic agents.

Conditions

Interventions

DRUG

Ketamine

25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received

DRUG

Placebo

0.5 mL of normal saline solution as a placebo in one pulverisation per nostril

Sponsors & Collaborators

  • University of Monastir

    lead OTHER

Principal Investigators

  • Nouira Semir, Professor · university Hospital of Monastir

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2018-12-01
Completion
2018-12-01

Countries

  • Tunisia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03233035 on ClinicalTrials.gov